Biotech | February 05, 2021
Biocon Biologics to offer its oncology biosimilars in 30+ countries
The partnership is a significant step in delivering advanced cancer therapies to patients.
The partnership is a significant step in delivering advanced cancer therapies to patients.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Subscribe To Our Newsletter & Stay Updated
